Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02736617
Title Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

mantle cell lymphoma

Therapies

Ibrutinib + Obinutuzumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.